Naunyn-Schmiedeberg's archives of pharmacology
METTL3/IGF2BP3 axis promotes gemcitabine resistance of pancreatic cancer cells through regulating USP33-mediated PAK1 deubiquitination and degradation.
Ling He, Xiongbing Li, Yaolan Zhen, Jiao He, Chao Wang
Published: 202510.1007/s00210-025-04575-0
Abstract
Although gemcitabine (GEM) is the standard of care for most patients with pancreatic cancer (PC), its efficacy is limited by resistance development. Furthermore, p21-activated kinase-1 (PAK1) has been demonstrated to be involved in regulating the dev…
Preview only. Read the full abstract at the source